Medical - Devices
Compare Stocks
5 / 10Stock Comparison
IRMD vs LNTH vs GEHC vs MDT vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Medical - Healthcare Information Services
Medical - Devices
Medical - Instruments & Supplies
IRMD vs LNTH vs GEHC vs MDT vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic | Medical - Healthcare Information Services | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $1.11B | $5.92B | $27.90B | $99.94B | $161.07B |
| Revenue (TTM) | $86M | $1.55B | $19.95B | $35.48B | $10.58B |
| Net Income (TTM) | $24M | $279M | $1.50B | $4.61B | $2.98B |
| Gross Margin | 76.8% | 60.5% | 42.5% | 61.9% | 66.3% |
| Operating Margin | 32.4% | 18.8% | 12.5% | 17.9% | 30.5% |
| Forward P/E | 42.9x | 17.5x | 12.4x | 14.1x | 43.8x |
| Total Debt | $0.00 | $738K | $10.00B | $28.52B | $303M |
| Cash & Equiv. | $51M | $359M | $4.51B | $2.22B | $3.37B |
IRMD vs LNTH vs GEHC vs MDT vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 22 | May 26 | Return |
|---|---|---|---|
| IRadimed Corporation (IRMD) | 100 | 306.6 | +206.6% |
| Lantheus Holdings, … (LNTH) | 100 | 178.6 | +78.6% |
| GE HealthCare Techn… (GEHC) | 100 | 105.1 | +5.1% |
| Medtronic plc (MDT) | 100 | 100.3 | +0.3% |
| Intuitive Surgical,… (ISRG) | 100 | 170.9 | +70.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IRMD vs LNTH vs GEHC vs MDT vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IRMD is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.58 vs MDT's 36.00
- Lower P/E (42.9x vs 43.8x), PEG 0.58 vs 2.01
- +72.4% vs ISRG's -15.4%
LNTH is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 41.9% 10Y total return vs ISRG's 5.5%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
Among these 5 stocks, GEHC doesn't own a clear edge in any measured category.
MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Beta 0.47 vs GEHC's 1.37, lower leverage
- 3.6% yield, 36-year raise streak, vs IRMD's 1.3%, (2 stocks pay no dividend)
ISRG ranks third and is worth considering specifically for growth exposure.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 20.5% revenue growth vs LNTH's 0.5%
- 28.2% margin vs GEHC's 7.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs LNTH's 0.5% | |
| Value | Lower P/E (42.9x vs 43.8x), PEG 0.58 vs 2.01 | |
| Quality / Margins | 28.2% margin vs GEHC's 7.5% | |
| Stability / Safety | Beta 0.47 vs GEHC's 1.37, lower leverage | |
| Dividends | 3.6% yield, 36-year raise streak, vs IRMD's 1.3%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +72.4% vs ISRG's -15.4% | |
| Efficiency (ROA) | 175.8% ROA vs GEHC's 4.1%, ROIC 6.0% vs 13.3% |
IRMD vs LNTH vs GEHC vs MDT vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
IRMD vs LNTH vs GEHC vs MDT vs ISRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IRMD leads in 2 of 6 categories
GEHC leads 1 • MDT leads 1 • LNTH leads 0 • ISRG leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
IRMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 411.3x IRMD's $86M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to GEHC's 7.5%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $86M | $1.5B | $20.0B | $35.5B | $10.6B |
| EBITDAEarnings before interest/tax | $30M | $347M | $3.3B | $9.4B | $3.8B |
| Net IncomeAfter-tax profit | $24M | $279M | $1.5B | $4.6B | $3.0B |
| Free Cash FlowCash after capex | $24M | $372M | $1.5B | $5.4B | $2.8B |
| Gross MarginGross profit ÷ Revenue | +76.8% | +60.5% | +42.5% | +61.9% | +66.3% |
| Operating MarginEBIT ÷ Revenue | +32.4% | +18.8% | +12.5% | +17.9% | +30.5% |
| Net MarginNet income ÷ Revenue | +27.4% | +18.0% | +7.5% | +13.0% | +28.2% |
| FCF MarginFCF ÷ Revenue | +27.9% | +24.0% | +7.6% | +15.2% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +12.7% | +1.2% | +7.4% | +8.8% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +21.6% | +76.5% | -30.9% | -11.9% | +18.8% |
Valuation Metrics
GEHC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 13.5x trailing earnings, GEHC trades at a 77% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), IRMD offers better value at 0.67x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.1B | $5.9B | $27.9B | $99.9B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $5.6B | $33.4B | $126.2B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | 49.57x | 26.69x | 13.48x | 21.60x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | 42.94x | 17.52x | 12.40x | 14.13x | 43.84x |
| PEG RatioP/E ÷ EPS growth rate | 0.67x | — | 19.78x | 36.00x | 2.65x |
| EV / EBITDAEnterprise value multiple | 37.07x | 14.61x | 10.00x | 14.32x | 43.62x |
| Price / SalesMarket cap ÷ Revenue | 13.23x | 3.84x | 1.35x | 2.98x | 16.00x |
| Price / BookPrice ÷ Book value/share | 11.78x | 5.72x | 2.66x | 2.08x | 9.17x |
| Price / FCFMarket cap ÷ FCF | 64.53x | 16.73x | 18.53x | 19.28x | 64.67x |
Profitability & Efficiency
IRMD leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
IRMD delivers a 24.5% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $9 for MDT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to GEHC's 0.94x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs GEHC's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +24.5% | +24.3% | +14.4% | +9.4% | +16.9% |
| ROA (TTM)Return on assets | +21.3% | +12.4% | +4.1% | +175.8% | +14.8% |
| ROICReturn on invested capital | +50.2% | +30.6% | +13.3% | +6.0% | +15.0% |
| ROCEReturn on capital employed | +27.8% | +17.1% | +10.8% | +7.5% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 4 | 6 | 6 |
| Debt / EquityFinancial leverage | — | 0.00x | 0.94x | 0.59x | 0.02x |
| Net DebtTotal debt minus cash | -$51M | -$358M | $5.5B | $26.3B | -$3.1B |
| Cash & Equiv.Liquid assets | $51M | $359M | $4.5B | $2.2B | $3.4B |
| Total DebtShort + long-term debt | $0 | $738,000 | $10.0B | $28.5B | $303M |
| Interest CoverageEBIT ÷ Interest expense | — | 11.72x | 5.35x | 9.08x | — |
Total Returns (Dividends Reinvested)
Evenly matched — IRMD and LNTH each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $7,230 for MDT. Over the past 12 months, IRMD leads with a +72.4% total return vs ISRG's -15.4%. The 3-year compound annual growth rate (CAGR) favors IRMD at 23.3% vs GEHC's -8.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.0% | +35.3% | -25.9% | -18.1% | -19.3% |
| 1-Year ReturnPast 12 months | +72.4% | +13.1% | -10.7% | -2.8% | -15.4% |
| 3-Year ReturnCumulative with dividends | +87.6% | -4.0% | -22.2% | -4.2% | +49.6% |
| 5-Year ReturnCumulative with dividends | +214.1% | +314.2% | +2.9% | -27.7% | +58.7% |
| 10-Year ReturnCumulative with dividends | +433.9% | +4192.5% | +2.9% | +26.5% | +554.2% |
| CAGR (3Y)Annualised 3-year return | +23.3% | -1.4% | -8.0% | -1.4% | +14.4% |
Risk & Volatility
Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than GEHC's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs GEHC's 68.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.85x | 0.47x | 1.37x | 0.47x | 1.02x |
| 52-Week HighHighest price in past year | $107.90 | $93.00 | $89.77 | $106.33 | $603.88 |
| 52-Week LowLowest price in past year | $50.61 | $47.25 | $58.75 | $77.16 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +80.4% | +97.8% | +68.3% | +73.3% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 61.2 | 32.1 | 27.3 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 91K | 886K | 4.3M | 7.8M | 1.8M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: IRMD as "Buy", LNTH as "Buy", GEHC as "Buy", MDT as "Buy", ISRG as "Buy". Consensus price targets imply 40.5% upside for MDT (target: $110) vs 11.0% for LNTH (target: $101). For income investors, MDT offers the higher dividend yield at 3.57% vs GEHC's 0.23%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $120.00 | $101.00 | $84.00 | $109.50 | $622.60 |
| # AnalystsCovering analysts | 2 | 17 | 18 | 49 | 55 |
| Dividend YieldAnnual dividend ÷ price | +1.3% | — | +0.2% | +3.6% | — |
| Dividend StreakConsecutive years of raises | 4 | 0 | 3 | 36 | — |
| Dividend / ShareAnnual DPS | $1.17 | — | $0.14 | $2.78 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.1% | +0.7% | +3.2% | +1.4% |
IRMD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GEHC leads in 1 (Valuation Metrics). 2 tied.
IRMD vs LNTH vs GEHC vs MDT vs ISRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IRMD or LNTH or GEHC or MDT or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). GE HealthCare Technologies Inc. (GEHC) offers the better valuation at 13. 5x trailing P/E (12. 4x forward), making it the more compelling value choice. Analysts rate IRadimed Corporation (IRMD) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IRMD or LNTH or GEHC or MDT or ISRG?
On trailing P/E, GE HealthCare Technologies Inc.
(GEHC) is the cheapest at 13. 5x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, GE HealthCare Technologies Inc. is actually cheaper at 12. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IRadimed Corporation wins at 0. 58x versus Medtronic plc's 36. 00x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — IRMD or LNTH or GEHC or MDT or ISRG?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +314. 2%, compared to -27. 7% for Medtronic plc (MDT). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus GEHC's +2. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IRMD or LNTH or GEHC or MDT or ISRG?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus GE HealthCare Technologies Inc. 's 1. 37β — meaning GEHC is approximately 193% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 94% for GE HealthCare Technologies Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — IRMD or LNTH or GEHC or MDT or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IRMD or LNTH or GEHC or MDT or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus 10. 1% for GE HealthCare Technologies Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRMD leads at 31. 2% versus 13. 4% for GEHC. At the gross margin level — before operating expenses — IRMD leads at 76. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IRMD or LNTH or GEHC or MDT or ISRG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, IRadimed Corporation (IRMD) is the more undervalued stock at a PEG of 0. 58x versus Medtronic plc's 36. 00x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, GE HealthCare Technologies Inc. (GEHC) trades at 12. 4x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 31. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDT: 40. 5% to $109. 50.
08Which pays a better dividend — IRMD or LNTH or GEHC or MDT or ISRG?
In this comparison, MDT (3.
6% yield), IRMD (1. 3% yield), GEHC (0. 2% yield) pay a dividend. LNTH, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is IRMD or LNTH or GEHC or MDT or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
47), 3. 6% yield). Both have compounded well over 10 years (MDT: +26. 5%, GEHC: +2. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IRMD and LNTH and GEHC and MDT and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IRMD is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; GEHC is a mid-cap deep-value stock; MDT is a mid-cap income-oriented stock; ISRG is a mid-cap high-growth stock. IRMD, MDT pay a dividend while LNTH, GEHC, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.